Drug intelligence / Profile preview

filgrastim + thrombopoietin

Development stage: Preclinical
Lead developer: Amgen
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

The combination of filgrastim (a granulocyte colony-stimulating factor) and thrombopoietin (a megakaryocyte growth and development factor) is used to enhance mobilization of peripheral blood progenitor cells and improve hematopoietic recovery. Filgrastim stimulates neutrophil production while thrombopoietin increases platelet production. This combination has shown synergistic effects in mobilizing peripheral blood progenitor cells, decreasing the number of apheresis procedures required, and potentially accelerating hematopoietic recovery following high-dose chemotherapy.

Other names: G-CSF + TPO

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on filgrastim + thrombopoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on filgrastim + thrombopoietin.

Explore the full profile